- Home
- SURG vs KYNB Comparison
SURG vs KYNB Comparison
Compare SURG & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SURG | KYNB |
|---|---|---|
| Founded | 2006 | 1993 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 31.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SURG | KYNB |
|---|---|---|
| Price | $0.80 | $6.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.75 | N/A |
| AVG Volume (30 Days) | ★ 179.6K | 36.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.78 | N/A |
| Revenue Next Year | $113.46 | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $6.72 |
| 52 Week High | $3.47 | $9.58 |
Technical Indicators
Market Signals| Indicator | SURG | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 32.77 | 37.10 |
| Support Level | $0.75 | N/A |
| Resistance Level | $0.95 | $8.89 |
| Average True Range (ATR) | 0.06 | 0.48 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 14.86 | 9.05 |
Price Performance
Historical ComparisonAbout SURG SurgePays Inc.
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.